ArticleJournal of clinical medicine2021
Left Ventricular Diastolic Function Following Anthracycline-Based Chemotherapy in Patients with Breast Cancer without Previous Cardiac Disease-A Meta-Analysis.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Can Biomarker-Based Monitoring Detect the Early Development of Diastolic Dysfunction During Chemotherapy?Medicina (Kaunas, Lithuania) · 2026Observational
- Chemotherapy-Induced Right Ventricular Dysfunction.Medicina (Kaunas, Lithuania) · 2026Review
- An echocardiographic study of right ventricular function and pulmonary systolic pressure in patients treated with anthracyclines.Journal of cardiovascular imaging · 2026Article
- How to Use Multimodality Imaging in Cardio-Oncology.Journal of cardiovascular development and disease · 2026Review
- Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis.Cardio-oncology (London, England) · 2025Review
- Machine learning based radiomics model to predict radiotherapy induced cardiotoxicity in breast cancer.Journal of applied clinical medical physics · 2025Article
- Advances in cardiac ultrasound speckle tracking technology for assessing left ventricular systolic function after adjuvant radiotherapy following breast-conserving surgery for breast cancer.American journal of translational research · 2025Review
- Comparison of Diagnostic Parameters of Acute Coronary Syndromes in Patients with and without Cancer: A Multifactorial Analysis.Current oncology (Toronto, Ont.) · 2024Article
- Echocardiographic Assessment of Left Ventricular Function in Three Oncologic Therapeutic Modalities in Women with Breast Cancer: The ONCO-ECHO Multicenter Study.Journal of clinical medicine · 2024Article
- Tales from the future-nuclear cardio-oncology, from prediction to diagnosis and monitoring.European heart journal. Cardiovascular Imaging · 2023Review
- Radial arterial waves for chemotherapy- and radiotherapy-related myocardial damage identification in patients with breast cancer.BioMedicine · 2023Article
- Cardiotoxicity among socioeconomically marginalized breast cancer patients.Breast cancer research and treatment · 2022Article
- Reproducibility assessment of a biomechanical model-based elasticity imaging method for identifying changes in left ventricular mechanical stiffness.Journal of medical imaging (Bellingham, Wash.) · 2022Article
- Regulation of Transplanted Cell Homing by FGF1 and PDGFB after Doxorubicin Myocardial Injury.Cells · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnthracycline-based chemotherapy (ANT) remains among the most effective therapies for breast cancer. Cardiotoxicity from ANT represents a severe adverse event and may predominantly manifest as heart failure. While it is well-recognised that left ventricular systolic heart failure assessment is key in ANT-treated patients, less is known about the relevance of LV diastolic functional impairment and its characterisation.
methodsStudies reporting on echocardiographic diastolic function parameters before and after ANT in breast cancer patients without cardiac disease were included. We evaluated pulsed wave (E/A ratio and mitral E-wave deceleration time (EDT)) and tissue Doppler (mean velocities of the mitral ring in the early diastole (e') and E/e' ratio) echocardiographic parameters.
resultsA total of 892 patients from 13 studies were included. E/A ratio was significantly reduced at the end of ANT while EDT was not influenced by ANT. Additionally, e' and E/e' ratio showed no significant change after ANT. A modest reduction in LV ejection fraction and global longitudinal strain was observed at the end of ANT therapy.
conclusionsANT had a modest early impact on E/A ratio, without changing EDT, e', or E/e' in patients with breast cancer without cardiac disease. Randomised studies on larger populations, using new parameters are required to define the role of diastolic dysfunction in the early diagnosis of ANT-induced cardiotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.